Growth Metrics

10x Genomics (TXG) R&D In Process (2018 - 2020)

10x Genomics recorded quarterly R&D In Process of $406.9 million in Q4 2020, up 901.33% quarter-over-quarter from $40.6 million in Q3 2020.

10x Genomics' R&D In Process history runs 2 years deep, the most recent figure standing at $406.9 million for Q4 2020.

  • In Q4 2020, R&D In Process changed N/A year-over-year to $406.9 million; the TTM figure through Dec 2021 stood at $447.5 million (changed 0.0% YoY), while the FY2020 annual figure was $447.5 million, changed N/A from the prior year.
  • R&D In Process came in at $406.9 million for Q4 2020 at 10x Genomics, up from $40.6 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $406.9 million in Q4 2020 to a low of $16.1 million in Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D In Process (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn -
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn -
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn -
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn -
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn -
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn -
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn -
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn -
10 Teladoc Health 1.42 Bn 672.39 Mn 562.57 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2020 406.91 Mn
Sep 30, 2020 40.64 Mn
Dec 31, 2018 40.05 Mn
Sep 30, 2018 16.10 Mn